ArticleEpidemiology and infection2007
Emerging fluoroquinolone and macrolide resistance of Campylobacter jejuni and Campylobacter coli isolates and their serotypes in Thai children from 1991 to 2000.
Article in Epidemiology and infection, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Prevalence and antimicrobial resistance ofOne health (Amsterdam, Netherlands) · 2025Review
- Pan-Genome Analysis of Campylobacter: Insights on the Genomic Diversity and Virulence Profile.Microbiology spectrum · 2022Article
- Waterborne Isolates ofFrontiers in microbiology · 2021Article
- Antibiotic Resistance ofAntimicrobial agents and chemotherapy · 2019Article
- Current and Potential Treatments for ReducingFrontiers in microbiology · 2017Review
- Incidence ofGut pathogens · 2017Article
- Virulence and Antimicrobial Resistance inScientifica · 2017Article
- Regulation of oxidative stress resistance in Campylobacter jejuni, a microaerophilic foodborne pathogen.Frontiers in microbiology · 2015Review
- Synergistic anti-Campylobacter jejuni activity of fluoroquinolone and macrolide antibiotics with phenolic compounds.Frontiers in microbiology · 2015Article
- Antimicrobial resistance of Campylobacter isolates from retail meat in the United States between 2002 and 2007.Applied and environmental microbiology · 2010Article
- PFGE, Lior serotype, and antimicrobial resistance patterns among Campylobacter jejuni isolated from travelers and US military personnel with acute diarrhea in Thailand, 1998-2003.Gut pathogens · 2010Article
- Case-control study of diarrheal disease etiology in a remote rural area in Western Thailand.The American journal of tropical medicine and hygiene · 2010Article
- Characterization of two Campylobacter jejuni strains for use in volunteer experimental-infection studies.Infection and immunity · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated fluoroquinolone, macrolide resistances and serotype distributions among Campylobacter jejuni and Campylobacter coli isolated from children in Bangkok and rural settings during 1991-2000. Phenotypic identification, serotyping, and susceptibility testing were performed by standard microbiological procedures. The predominant serotypes of C. jejuni were Lior 36, 2 and 4 and of C. coli were Lior 8, 29 and 55. Resistance to nalidixic acid increased significantly during 1991-2000 and the frequency of isolates resistant to both nalidixic acid and ciprofloxacin in Bangkok was significantly greater than in rural settings. In 1996-2000, a significant trend was observed in C. jejuni isolates resistant to ciprofloxacin from Bangkok but not for macrolide resistance from both settings. In summary, fluoroquinolone resistance among C. jejuni and C. coli isolates became widespread in both Bangkok and rural settings in Thailand in the 1990s while widespread resistance to macrolides was undetected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.